男性慢性肝病患者勃起功能障碍研究进展*

doi:10.3969/j.issn.1672-5069.2021.06.042

Abstract

Abstract: Objective Liver is an important organ for the metabolism of sex hormones, lipids and other substances. Male patients with chronic liver disease often suffer from a variety of dysfunctions, such as sex hormone metabolism, glucose and lipid metabolism and mental and psychological disorder. Erectile dysfunction is easy to occur, which affects the physical and mental health and the family life of patients.Existing studies have shown that the prevalence of male erectile dysfunction in patients with chronic liver disease was 24.6% to 85%, the prevalence in chronic hepatitis patients was 8.6% to 78%, and in patients with cirrhosis was 41.2% to 92%.In this paper, we reviewed the incidence, impacting factors, possible pathogenesis, and treatment of erectile dysfunctions in male patients with chronic liver disease.

Key words: Cirrhosis, Chronic hepatitis, Erectile dysfunctions, Phosphodiesterase inhibitor 5

Deng Jiang, Shi Juanjuan, Dang Shuangsuo. Erectile dysfunction in male patients with chronic liver diseases[J]. Journal of Practical Hepatology, 2021, 24(6): 934-937.

References

[1] Zhang X, Yang B, Li N, et al. Prevalence and risk factors for erectile dysfunction in chinese adult males. J Sex Med, 2017, 14(10): 1201-1208.
[2] Yafi F A, Jenkins L, Albersen M, et al. Erectile dysfunction. Nat Rev Dis Primers, 2016, 2: 16003.
[3] Ludwig W, Phillips M. Organic causes of erectile dysfunction in men under 40. Urol Int, 2014, 92(1): 1-6.
[4] 方庆华, 胡雷, 陈栋. 代谢综合征与勃起功能障碍相关机制的研究进展. 中华肥胖与代谢病电子杂志, 2017, 3(3): 158-161.
[5] Kim M, Kim S Y, Rou W S, et al. Erectile dysfunction in patients with liver disease related to chronic hepatitis B. Clin Mol Hepatol, 2015, 21(4): 352-357.
[6] Toda K, Miwa Y, Kuriyama S, et al. Erectile dysfunction in patients with chronic viral liver disease: its relevance to protein malnutrition. J Gastroenterol, 2005, 40(9): 894-900.
[7] Liu J, Liang W, Jing W, et al. Countdown to 2030: eliminating hepatitis b disease, China. Bull World Health Organ, 2019, 97(3): 230-238.
[8] Gentile I, Fusco F, Buonomo A R, et al. Prevalence and risk factors of erectile dysfunction in patients with hepatitis B virus or hepatitis C virus or chronic liver disease: results from a prospective study. Sex Health, 2018, 15(5): 408-412.
[9] Paternostro R, Heinisch B B, Reiberger T, Et Al. Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. Liver Int, 2018, 38(8): 1427-1436.
[10] Chrysant S G. Antihypertensive therapy causes erectile dysfunction. Curr Opin Cardiol, 2015, 30(4): 383-390.
[11] Thakur J, Rathi S, Grover S, et al. Tadalafil, a phosphodiesterase-5 inhibitor, improves erectile dysfunction in patients with liver cirrhosis. J Clin Exp Hepatol, 2019, 9(3): 312-317.
[12] Simsek I, Aslan G, Akarsu M, et al. Assessment of sexual functions in patients with chronic liver disease. Int J Impot Res, 2005, 17(4): 343-345.
[13] Cornely C M, Schade R R, Van Thiel D H, et al. Chronic advanced liver disease and impotence: cause and effect?Hepatology, 1984, 4(6): 1227-1230.
[14] Rachdaoui N, Sarkar D K. Pathophysiology of the effects of alcohol abuse on the endocrine system. Alcohol Res, 2017, 38(2): 255-276.
[15] Durazzo M, Premoli A, Di Bisceglie C, et al. Male sexual disturbances in liver diseases: what do we know? J Endocrinol Invest, 2010, 33(7): 501-505.
[16] Siervo G E, Vieira H R, Ogo F M, et al. Spermatic and testicular damages in rats exposed to ethanol: influence of lipid peroxidation but not testosterone. Toxicology, 2015, 330: 1-8.
[17] Lang Z W. Distribution of hepatitis B virus in testicle tissue in patients with hepatitis B infection. Zhonghua Yi Xue Za Zhi, 1993, 73(6): 329-331, 379.
[18] Sun P, Zheng J, She G, et al. Expression pattern of asialoglycoprotein receptor in human testis. Cell Tissue Res, 2013, 352(3): 761-768.
[19] Huang F, Long F, Yu W, et al. High prevalence of hepatitis E virus in semen of infertile male and causes testis damage. Gut, 2018, 67(6): 1199-1201.
[20] Mansour W, Lemoine M, Neri Pinto F, et al. Markers of hepatitis delta virus infection can be detected in follicular fluid and semen. J Clin Virol, 2014, 61(2): 279-281.
[21] Ma B O, Shim S G, Yang H J. Association of erectile dysfunction with depression in patients with chronic viral hepatitis. World J Gastroenterol, 2015, 21(18): 5641-5646.
[22] Chung S D, Keller J J, Liang Y C, et al. Association between viral hepatitis and erectile dysfunction: a population-based case-control analysis. J Sex Med, 2012, 9(5): 1295-1302.
[23] Pircher J, Czermak T, Merkle M, et al. hepatitis c virus induced endothelial inflammatory response depends on the functional expression of tnfalpha receptor subtype 2. PLoS One, 2014, 9(11): e113351.
[24] Maimone S, Saffioti F, Oliva G, et al. Erectile dysfunction in compensated liver cirrhosis. Dig Liver Dis, 2019, 51(6): 843-849.
[25] Calzo J P, Austin S B, Charlton B M, et al. Erectile dysfunction in a sample of sexually active young adult men from a us cohort: demographic, metabolic, and mental health correlates. J Urol, 2020, 101097ju0000000000001367.
[26] Ning L, Yang L. Hypertension might be a risk factor for erectile dysfunction: a meta-analysis. Andrologia, 2017, 49(4): e12644.
[27] Dove L M, Rosen R C, Ramcharran D, et al. Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C. Gastroenterology, 2009, 137(3): 873-884, 84.e1.
[28] Durazzo M, Premoli A, Di Bisceglie C, et al. Alterations of seminal and hormonal parameters: an extrahepatic manifestation of hcv infection?World J Gastroenterol, 2006, 12(19): 3073-3076.
[29] El-Sakka A I. Dehydroepiandrosterone and erectile function: a review. World J Mens Health, 2018, 36(3): 183-191.
[30] Raff H, Sluss P M. Pre-analytical issues for testosterone and estradiol assays. Steroids, 2008, 73(13): 1297-1304.
[31] Sinclair M, Grossmann M, Gow P J, et al. Testosterone in men with advanced liver disease: abnormalities and implications. J Gastroenterol Hepatol, 2015, 30(2): 244-251.
[32] Sinclair M, Gow P J, Angus P W, et al. High circulating oestrone and low testosterone correlate with adverse clinical outcomes in men with advanced liver disease. Liver Int, 2016, 36(11): 1619-1627.
[33] Paternostro R, Heinisch B B, Reiberger T, et al. Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis. Hepatol Res, 2019, 49(2): 201-211.
[34] Zifroni A, Schiavi R C, Schaffner F. Sexual function and testosterone levels in men with nonalcoholic liver disease. Hepatology, 1991, 14(3): 479.
[35] 倪东升, 王天才. 一氧化氮在肝硬化大鼠睾丸功能障碍发生中的作用. 中华肝脏病杂志, 2002, 10(4): 294-296.
[36] Gluud C, Wantzin P, Eriksen J. No effect of oral testosterone treatment on sexual dysfunction in alcoholic cirrhotic men. Gastroenterology, 1988, 95(6): 1582-7.
[37] Porst H, Gacci M, Buttner H, et al. Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies. European urology, 2014, 65(2): 455-464.
[38] 黄燕平, 郑伏甫, 姚凤娟, 等. 小剂量每日服用他达那非改善勃起功能障碍患者内皮舒张功能及勃起硬度的研究. 中华男科学杂志, 2010, 16(11): 1052-5.

Erectile dysfunction in male patients with chronic liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Jiang Hao, Zhang Wen, Chen Xia. Peginterferon-α and ribavirin combination in treatment of patients with chronic hepatitis C and its impact on resting energy expenditure and nutritional status [J]. Journal of Practical Hepatology, 2021, 24(6): 815-818.
[2]	Wu Xiaofeng, Huang Yi, Yang Ruxing,et al. Blood serine protease inhibitor A1 gene polymorphism in patients with primary biliary cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 855-858.
[3]	Shi Cuicui, Liu Yanjun, Zhang Ruinan, et al. Dyslipidemia in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 859-862.
[4]	Liu Mei, Shi Yonghong, Ying Juan, et al. Prevalence of nosocomial infection and resistance of pathogens in patients with decompensated liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 863-866.
[5]	Liu Yuling, Zhen Zengguo, Wang Huijuan, et al. Effects of probiotics on intestinal barrier function of patients with liver cirrhosis complicated by spontaneous bacterial peritonitis [J]. Journal of Practical Hepatology, 2021, 24(6): 867-870.
[6]	Xing Li, Du Qianying, Jiang Yanli, et al. Impact of segmented injection of contrast agent on hepatic vein imaging by CT angiography in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 871-874.
[7]	Huang Liou, Wu Chunrong, Xu Dan, et al. Efficacy of continuous renal replacement therapy without heparinization in patients with liver cirrhosis complicated by hepatic encephalopathy [J]. Journal of Practical Hepatology, 2021, 24(6): 875-878.
[8]	Ye Dong, Zhang Junxia, LiJie, et al. Risk factors of rebleeding in hepatitis B liver cirrhotics with esophageal varices bleeding after endoscopic variceal ligation [J]. Journal of Practical Hepatology, 2021, 24(6): 879-882.
[9]	Han Chengmei, Han Yongfeng, Wang Chunhua. Risk factors for acute kidney injury in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 883-886.
[10]	Wang Jing, Bi Ning, Fang Liang, et al. Efficacy of transarterial intrahepatic transplantation of autologous bone marrow stem cells in the treatment of patients with decompensated hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 887-890.
[11]	Xue Kui, Xu Yinhai, Zhang Jian. Changes of serum thrombopoietin levels and its relationship with peripheral blood platelet counts in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 891-894.
[12]	Han Lichou, Xu Wang, Han Dan, et al. Observation of gastric mucosal lesions in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 895-898.
[13]	Shu Qinghua, Zhang Nannan, Ge Yongsheng. Impact of HCV genotypes on the treatment response of recombinant human interferon α-2a in patients with chronic hepatitis C and hepatitis C liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 899-902.
[14]	Tan Fenglei, Wu Liangliang, Deng Zerun, et al. Nocturnal snack in patients with liver cirrhosis: a Meta analysis [J]. Journal of Practical Hepatology, 2021, 24(5): 625-628.
[15]	Li Wei, Song Weidong, Xie Batu Baiyin. Efficacy of esophageal variceal ligation and transjugular intrahepatic portosystemic shunt in treatment of patients with liver cirrhosis and esophageal varices bleeding [J]. Journal of Practical Hepatology, 2021, 24(5): 629-632.